Mutual of America Capital Management LLC Sells 12,146 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Mutual of America Capital Management LLC Sells 12,146 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Mutual of America Capital Management LLC cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 5.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 192,599 shares of the biopharmaceutical company's stock after selling 12,146 shares during the period. Mutual of America Capital Management LLC owned 0.14% of Halozyme Therapeutics worth $7,615,000 at the end of the most recent reporting period.
根據Halozyme治療公司最近向美國證券交易委員會披露的信息,美國互惠資本管理公司在第三季度將其在Halozyme治療公司(納斯達克:Halo-Get評級)的股份削減了5.9%。該公司在此期間出售了12,146股後,擁有這家生物製藥公司192,599股股票。在最近的報告期結束時,美國資本管理公司共同擁有Halozyme Treeutics公司0.14%的股份,價值761.5萬美元。
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Financial Gravity Asset Management Inc. bought a new stake in shares of Halozyme Therapeutics during the third quarter valued at about $2,220,000. First Horizon Advisors Inc. increased its position in shares of Halozyme Therapeutics by 188.8% during the second quarter. First Horizon Advisors Inc. now owns 722 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 472 shares during the period. Meeder Asset Management Inc. increased its position in shares of Halozyme Therapeutics by 223.6% during the second quarter. Meeder Asset Management Inc. now owns 741 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 512 shares during the period. Brown Brothers Harriman & Co. bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at about $35,000. Finally, Selective Wealth Management Inc. bought a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $44,000. 96.32% of the stock is currently owned by institutional investors.
其他對衝基金和其他機構投資者最近也調整了對該公司的持股。金融重力資產管理公司在第三季度購買了Halozyme Treateutics的新股,價值約222萬美元。First Horizon Advisors Inc.在第二季度將其在Halozyme Treateutics的股票頭寸增加了188.8%。First Horizon Advisors Inc.現在持有這家生物製藥公司722股股票,價值3.2萬美元,在此期間又購買了472股。Meeder資產管理公司在第二季度將其在Halozyme Treateutics的股票頭寸增加了223.6%。Meeder Asset Management Inc.現在持有這家生物製藥公司741股股票,價值33,000美元,在此期間又購買了512股。布朗兄弟哈里曼公司在第二季度購買了Halozyme Treateutics的新股,價值約3.5萬美元。最後,選擇性財富管理公司在第二季度購買了價值約44,000美元的Halozyme Treeutics股票的新頭寸。96.32%的股票目前由機構投資者持有。
Halozyme Therapeutics Stock Performance
Halozyme治療藥物的股票表現
NASDAQ:HALO opened at $52.87 on Friday. The firm has a market cap of $7.15 billion, a PE ratio of 35.48, a price-to-earnings-growth ratio of 0.68 and a beta of 1.22. Halozyme Therapeutics, Inc. has a fifty-two week low of $32.00 and a fifty-two week high of $59.46. The company has a debt-to-equity ratio of 15.37, a quick ratio of 5.03 and a current ratio of 5.97. The business has a 50 day moving average price of $55.00 and a 200-day moving average price of $48.50.
納斯達克:光環上週五開盤報52.87美元。該公司市值為71.5億美元,市盈率為35.48倍,市盈率為0.68倍,貝塔係數為1.22。Halozyme治療公司的股價為52周低點32.00美元和52周高點59.46美元。該公司的債務權益比率為15.37,速動比率為5.03,流動比率為5.97。該業務的50日移動均線價格為55.00美元,200日移動均線價格為48.50美元。
Insider Buying and Selling
內幕買賣
In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $52.15, for a total transaction of $521,500.00. Following the completion of the transaction, the chief executive officer now owns 587,177 shares of the company's stock, valued at $30,621,280.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Nicole Labrosse sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $53.81, for a total transaction of $269,050.00. Following the sale, the chief financial officer now owns 4,045 shares in the company, valued at $217,661.45. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $52.15, for a total value of $521,500.00. Following the completion of the transaction, the chief executive officer now directly owns 587,177 shares in the company, valued at $30,621,280.55. The disclosure for this sale can be found here. Insiders sold 85,000 shares of company stock valued at $4,666,350 over the last quarter. 2.30% of the stock is owned by company insiders.
在Halozyme治療公司的其他消息中,首席執行官海倫·託利在11月17日星期四的一次交易中出售了10,000股該公司的股票。該股以52.15美元的平均價格出售,總成交金額為521,500.00美元。交易完成後,首席執行官現在擁有587,177股公司股票,價值30,621,280.55美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過這個環節。在其他新聞方面,首席財務官Nicole Labrosse在11月15日星期二的一筆交易中出售了5000股該公司股票。這些股票的平均價格為53.81美元,總成交額為269,050.00美元。出售後,這位首席財務官現在擁有該公司4045股,價值217,661.45美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可在這個環節。此外,首席執行官海倫·託利在11月17日星期四的一次交易中出售了10,000股公司股票。這些股票的平均價格為52.15美元,總價值為521,500.00美元。交易完成後,首席執行官現在直接擁有公司587,177股,價值30,621,280.55美元。關於這次銷售的披露可以找到這裏。內部人士在上個季度出售了8.5萬股公司股票,價值4666,350美元。2.30%的股份由公司內部人士持有。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
HALO has been the topic of several research analyst reports. SVB Leerink decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $61.00 and set an "outperform" rating on the stock in a research report on Wednesday, January 11th. StockNews.com initiated coverage on shares of Halozyme Therapeutics in a research report on Wednesday, October 12th. They issued a "hold" rating on the stock. JMP Securities upped their price objective on shares of Halozyme Therapeutics from $60.00 to $62.00 and gave the stock a "market outperform" rating in a research report on Wednesday, November 9th. Morgan Stanley upped their price objective on shares of Halozyme Therapeutics from $53.00 to $65.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 21st. Finally, JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $53.00 to $54.00 and gave the company an "overweight" rating in a research report on Tuesday, November 22nd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $59.63.
光環一直是幾份研究分析師報告的主題。SVB Leerink在1月11日星期三的一份研究報告中將Halozyme Treateutics的股票目標價從62.00美元下調至61.00美元,並對該股設定了“跑贏大盤”的評級。StockNews.com在10月12日星期三的一份研究報告中開始了對Halozyme治療公司股票的報道。他們對該股的評級為“持有”。JMP證券在11月9日星期三的一份研究報告中將Halozyme Treateutics的股票目標價從60.00美元上調至62.00美元,並給予該股票“市場表現優於大盤”的評級。12月21日,週三,摩根士丹利在一份研究報告中將Halozyme治療公司的股票目標價從53.00美元上調至65.00美元,並給予該股“增持”評級。最後,摩根大通公司在11月22日星期二的一份研究報告中將Halozyme治療公司的股票目標價從53.00美元上調至54.00美元,並給予該公司“增持”評級。一位研究分析師對該股的評級為持有,七位分析師對該公司股票的評級為買入。根據MarketBeat的數據,Halozyme治療公司目前的共識評級為“中等買入”,平均目標價為59.63美元。
Halozyme Therapeutics Company Profile
Halozyme治療公司簡介
(Get Rating)
(獲取評級)
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Halozyme治療公司在美國、瑞士、愛爾蘭、比利時、日本和國際上作為生物製藥技術平臺公司運營。該公司的產品基於Enhanze藥物輸送技術,這是一種獲得專利的重組人透明質酸酶(RHuPH20),使可注射生物製劑(如單抗和其他治療分子)以及小分子和液體能夠在皮下輸送。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- Ford Stock Going Forward After Big Earnings Flop
- Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
- Bright Green Corporation Future May be Getting Brighter
- Microsoft Fast Integrating AI Into Enterprise & Healthcare Suites
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- 免費獲取StockNews.com關於Halozyme治療的研究報告(Halo)
- 福特股票在盈利大幅下滑後繼續前進
- 英偉達股價上漲,投資者看好芯片製造商的人工智能業務
- 光明綠色公司的未來可能變得更加光明
- 微軟將人工智能快速集成到企業和醫療保健套件中
- 凱西·伍茲的方舟創新ETF將在2023年反彈?
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating).
想看看還有哪些對衝基金持有光環嗎?訪問HoldingsChannel.com獲取Halozyme治療公司(納斯達克:Halo-Get Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Halozyme治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Halozyme治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。